SpaceX Starship Explodes in Spectacular Fireball at Texas Test Facility
The upper stage prototype, designated Ship 36, exploded shortly before midnight local time on June 18 during routine preparations for an upcoming test flight.
SpaceX is in the midst of preparing for Starship's next fully integrated test, known as Flight 10. The last several tests haven't gone well, but this prototype never even left the ground. The explosion—as shown in spectacular footage from NASASpaceFlight.com—occurred at SpaceX's Massey facility, a test site located several miles from the launch mount at Starbase, Texas.
The 171-foot-tall (51-meter) Starship upper stage 'experienced a major anomaly while on a test stand at Starbase,' SpaceX said in a statement on X. 'A safety clear area around the site was maintained throughout the operation and all personnel are safe and accounted for.' The Starbase team is coordinating with local authorities to manage the aftermath of the incident, SpaceX said, adding that, while the company reported no threat to nearby communities, it urged the public to steer clear of the area as safety measures are carried out.
SpaceX CEO Elon Musk chimed in a few hours after the incident on X, brushing the incident off as 'Just a scratch.' He elaborated further this morning, saying the early data 'suggests a nitrogen COPV [composite overwrapped pressure vessel] in the payload bay failed below its proof pressure,' and that if this proves to be the case, it's the 'first time ever for this design.' A COPV is a lightweight tank made of composite fibers wrapped around a thin liner to store high-pressure fluids, according to NASA. No further details are known, but as SpaceNews points out, Starship was being prepared for a static fire test, and the explosion happened before the rocket had a chance to fire its Raptor engines.
A June 18 advisory from the Federal Aviation Administration pointed to June 29 as a potential date for Flight 10, but that seems unlikely now. SpaceX is in a bit of a slump right now, with this incident adding to the pile of recent setbacks. Flight 7 in January 2024 experienced a propellant leak and fire triggered by unexpected vibrations in the propulsion system. In March, Flight 8 was cut short by a hardware failure in one of the Raptor engines, while Flight 9 in May successfully reached space, but a leak led to loss of control and the vehicle broke apart during reentry.
SpaceX's Starship megarocket is built to carry people and cargo to the Moon, Mars, and other destinations around the solar system. It's a key part of NASA's Artemis program, which aims to land astronauts on the Moon by 2027, and is key to Elon Musk's goal of colonizing Mars.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Glucorem Shares Report on Blood Sugar Stabilization and Metabolic Glucose Transport Pathways (2025)
Formulated with AMPK-activating botanicals and GLUT-4 support compounds, Glucorem explores how non-stimulant glucose transport strategies are gaining momentum among wellness-focused consumers in 2025. New York, Aug. 02, 2025 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and Drug Administration. This article is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Please consult a licensed healthcare provider before beginning any new supplement, dietary, or lifestyle regimen. Glucorem is positioning itself at the center of a growing conversation around non-stimulant blood sugar management, combining modern ingredient transparency with a science-inspired approach to glucose stability. As discussions around AMPK activation, mitochondrial efficiency, and GLUT-4 receptor function continue to rise across search engines and forums, Glucorem's formula aligns with emerging consumer curiosity around next-generation support you purchase through this link, the publisher may receive a commission at no additional cost to you. Consumer Trend or Problem Shift Across wellness circles and search behavior patterns in 2025, a new focus is emerging: how to maintain stable blood sugar without relying on harsh stimulant-based interventions. Online forums, Google search trends, and TikTok comment threads are filled with questions like 'Why do I crash after meals?', 'Is there a way to support my metabolism naturally?', and 'What do GLUT-4 receptors really do?' One growing area of exploration centers around GLUT-4 glucose transporters, which help shuttle glucose into cells, particularly after meals. These receptors often come under stress when insulin signaling is overwhelmed — something that can occur not just from sugar-laden diets, but also from years of metabolic wear and tear. Paired with rising searches around 'AMPK activation' and 'mitochondrial support,' it's clear that wellness consumers are looking deeper than calorie counting or glycemic indexes. The shift is away from silver-bullet solutions and toward ingredient-first exploration. Search queries like 'how to mimic fasting without fasting,' 'GLUT-4 natural support,' and 'non-clinical insulin sensitivity' reflect an evolving curiosity that transcends traditional diet supplements. In this climate, brands that emphasize transparent formulas and science-aligned mechanisms — without crossing into medical territory — are resonating with a more research-savvy public. This consumer awareness is reshaping the entire blood sugar discussion. Rather than simply focusing on A1C or glucose numbers, many individuals are exploring their energy levels, post-meal patterns, cravings, and cognitive clarity — all as potential reflections of underlying glucose Structure and Use Glucorem is structured around a liquid delivery format, combining botanical ingredients and timing protocols designed to align with emerging interest in metabolic synergy. It does not operate as a replacement for prescribed medications or clinical oversight. Instead, the formulation represents a non-stimulant, informationally driven design inspired by layered systems like the AMPK pathway and GLUT-4 receptor activity. Central to its model is the GlycoBalance Cascade™ — a term describing the timed interaction of six plant compounds, each explored independently in wellness circles for their roles in metabolic behavior. These compounds are delivered sublingually (under the tongue), a format often discussed in supplement communities as a way to bypass traditional digestion and support faster uptake. This approach reflects trends around metabolic flexibility, where the goal is not just to manage post-meal glucose spikes, but to support overall glucose transport, inflammation control, and energy conversion — all without stimulants or synthetic additives. Each ingredient in Glucorem is positioned to align with an aspect of the blood sugar story that users are now researching independently. Public interest in turmeric root, for example, often centers on its role in inflammation and insulin receptor behavior. Bitter melon draws attention for its ability to mimic insulin-like activity. Resveratrol from Japanese knotweed is frequently mentioned alongside AMPK and mitochondrial health, while compounds like cinnamon bark and coriander seed have long been associated with post-meal balance. None of these ingredients are positioned as magic bullets. Instead, the structure of Glucorem reflects a convergence of user interest in transparency, timing, plant synergy, and metabolic literacy. As formulas shift toward educational positioning, Glucorem appears to follow a path now favored by supplement-conscious Transparency As ingredient-conscious consumers drive demand for transparency in supplement formulations, the components of Glucorem are receiving attention not just for their origin, but for how they reflect broader interest in metabolic health research. Each inclusion serves a function aligned with popular wellness frameworks — from AMPK activation to GLUT-4 transporter behavior — while remaining rooted in non-clinical, plant-based tradition. Turmeric root extract is one of the most searched ingredients in the wellness space, often associated with inflammation-related pathways and insulin receptor sensitivity. In blood sugar-focused conversations, turmeric's curcuminoid compounds are being explored in relation to how cells respond to insulin signals, and how metabolic flexibility can be supported without pharmacological interference. Cinnamon bark is another standout, with widespread coverage in public articles and short-form videos focusing on how it may influence post-meal blood sugar patterns. Search behavior reveals a sustained curiosity around its impact on fasting glucose levels and its connection to GLUT-4 activity — the cellular transporters that manage sugar uptake after meals. Bitter melon, long used in Eastern herbal systems, is frequently mentioned in discussions about insulin-mimicking plant compounds. It draws interest from users looking to understand how natural substances can work with the body's signaling systems without acting as direct substitutes for medical interventions. Japanese knotweed offers a rich source of resveratrol, a polyphenol increasingly linked in public forums to mitochondrial efficiency and AMPK activation. AMPK, or AMP-activated protein kinase, has emerged in search trends as a cellular energy switch — a regulatory enzyme that signals when the body should begin pulling from internal energy stores rather than relying on circulating glucose. This is a topic that resonates especially with users interested in mimicking fasting effects without altering their diets. Licorice root and coriander seed round out Glucorem's formula. Licorice is often sought out for its potential to help balance adrenal activity and modulate stress-related inflammation, while coriander seed is being explored in wellness content for its post-meal blood sugar stability properties. What makes Glucorem distinct in this space is not simply the presence of these ingredients, but their interaction. The formula is constructed with an awareness of synergistic potential — how one compound may support or amplify the action of another, forming a blend greater than the sum of its Behind the System As public understanding of metabolic health deepens, many consumers are shifting their focus from surface-level sugar control to the biological systems that influence glucose movement and energy production. Glucorem is designed with this systems-level perspective in mind, drawing on pathways now commonly referenced in public forums: AMPK activation, GLUT-4 support, and mitochondrial energy regulation. AMPK, or AMP-activated protein kinase, is a cellular enzyme that plays a key role in energy sensing. Often described as the body's metabolic 'master switch,' AMPK becomes activated during periods of low energy availability — such as during exercise or fasting — and signals the body to start burning stored fuel. In wellness discussions, AMPK activation is frequently associated with better glucose clearance, increased fat metabolism, and improved mitochondrial performance. Rather than attempting to mimic pharmaceutical AMPK modulators, Glucorem includes compounds like resveratrol (from Japanese knotweed) and bitter melon, which are publicly discussed for their potential influence on this pathway. These ingredients are gaining attention among those who wish to explore metabolic switching through non-stimulant, food-derived compounds. Another major focus of Glucorem's formulation is GLUT-4 transporter activity. GLUT-4 is a type of glucose transporter found in muscle and fat tissues, responsible for moving glucose from the bloodstream into cells — particularly after insulin is released in response to a meal. When GLUT-4 becomes less responsive, it can lead to glucose buildup in the blood and contribute to unstable energy patterns. In user-led discussions across Reddit and scientific commentary alike, GLUT-4 sensitivity is increasingly seen as a valuable area of exploration for individuals interested in long-term glucose balance. Ingredients like cinnamon bark and turmeric root have been highlighted in wellness blogs and keyword trend reports for their associations with GLUT-4 signaling and insulin receptor activity. The liquid, sublingual format of Glucorem also speaks to a growing interest in fast-absorbing delivery systems. While not a medication or injection, the under-the-tongue delivery method allows the body to absorb plant compounds through mucosal membranes — potentially bypassing some of the delays and breakdown that occur during digestion. Glucorem's structure, therefore, aligns with non-clinical interest in optimizing glucose usage, cellular energy allocation, and transporter function — themes that are rapidly expanding in consumer wellness content across It's For / Use Cases Glucorem is generating interest among a broad cross-section of individuals seeking to better understand and navigate their energy patterns, glucose response, and overall metabolic behavior. While not intended as a medical treatment, the formulation reflects a new class of non-stimulant wellness tools gaining traction among self-educating consumers. Many users encountering blood sugar fluctuation symptoms — such as mid-day fatigue, post-meal crashes, and persistent cravings — are now exploring ingredient stacks that address multiple pathways at once. This includes those who have already tried traditional approaches like low-glycemic diets or intermittent fasting but are now looking into cellular-level mechanisms like insulin receptor sensitivity and GLUT-4 transport regulation. Glucorem's formulation appears to resonate particularly with individuals curious about how energy metabolism connects to daily function. This includes professionals who experience brain fog after meals, those trying to regulate eating patterns, or individuals who've noticed that their energy and mood seem directly tied to blood sugar variability. Another group showing consistent interest in products like Glucorem includes people focused on preventative wellness. These are consumers who may not have been diagnosed with any condition, but who actively track their biometrics, use continuous glucose monitors, or follow biohacking forums. Their goal is not to treat illness, but to optimize performance — especially in areas like mitochondrial efficiency, recovery, and hormonal resilience. In addition, the sublingual format has appeal among those who have difficulty with capsules, or who are exploring rapid-delivery supplementation as part of a broader wellness routine. For individuals comparing tincture-based systems, the concept of layered absorption — where ingredients interact quickly and efficiently — is a differentiator that aligns with current supplement trends. Whether navigating fluctuating energy, researching AMPK activation, or experimenting with plant-based glucose support, Glucorem is part of a larger movement toward ingredient intelligence and formulation literacy. Its design reflects not a niche use case, but a growing wellness perspective that places metabolic balance at the center of daily or Objection Handling Public curiosity around Glucorem has led to several recurring questions across forums and wellness-focused channels. While the product is not positioned as a medical intervention, many individuals are exploring it within the context of their broader blood sugar and energy regulation efforts. The following frequently asked topics reflect that interest. One common question is: 'Will Glucorem work for me if I've struggled with blood sugar regulation for years?' While results are never guaranteed, many users exploring non-stimulant systems have expressed interest in Glucorem because of its layered approach. Rather than targeting a single mechanism, it's designed with a philosophy that combines multiple glucose-related pathways — including GLUT-4 transporter sensitivity, AMPK activation, and cellular inflammation reduction. Another topic of concern is safety: 'Can I take Glucorem alongside existing routines or medications?' The formulation is built with non-synthetic, plant-based compounds that are generally recognized as safe in wellness circles. However, the brand does not claim compatibility with any medical protocol and recommends consulting a licensed professional before adding new supplements to an existing regimen. A frequently searched topic is timing: 'How long does it take to see results?' While individual experiences vary, many consumers exploring metabolic support formulas report that initial shifts — such as fewer crashes, more stable energy, or reduced cravings — may occur within 1–2 weeks. That said, systems related to glucose regulation often benefit from consistency over time. For some, noticeable changes align more closely with a 90–180 day usage window. A unique question tied to Glucorem's structure is: 'How does the sublingual delivery make a difference?' The under-the-tongue format bypasses the digestive system, allowing active ingredients to begin absorption through mucosal membranes. This is of particular interest to users researching supplement bioavailability or comparing traditional capsules with more immediate delivery models. These questions reflect a larger trend: users want to understand how and why formulations work — not just whether they're popular. Glucorem's public-facing transparency and emphasis on layered plant synergy have helped position it as part of that educational Manufacturing, Distribution Glucorem is manufactured in the United States in a GMP-certified facility that follows industry-standard safety and quality protocols. Each batch undergoes routine quality checks to verify ingredient consistency, purity, and label accuracy — aligning with growing consumer interest in manufacturing transparency and traceability. The formula is non-GMO, vegan-friendly, and contains no artificial stimulants or additives. These characteristics are frequently highlighted in consumer reviews and blog content exploring the 'clean label' supplement movement, where formulation simplicity and sourcing accountability are increasingly prioritized. Every unit of Glucorem is bottled, sealed, and shipped from a domestic distribution center, allowing for timely fulfillment and order tracking. Users have noted this as a key benefit when comparing supplement delivery options — especially for wellness routines that require consistency in usage or resupply. The product is exclusively available through the official platform, which helps prevent unauthorized third-party sellers from distributing counterfeit or expired versions. This direct-to-consumer model ensures freshness, access to current ingredient disclosures, and full alignment with the brand's informational content and dosage instructions. Shipping options are available throughout the United States, and orders typically arrive within a few business days. For those seeking ongoing metabolic support or multi-bottle bundles, the distribution system is designed to accommodate long-term use without delays or stock Information Glucorem – Natural Support for Glucose Balance Email: curtisherring@ Phone (US): (888) 308 8896 Website: Final Disclaimer This article is for informational purposes only and does not constitute medical advice. The statements discussed have not been evaluated by the Food and Drug Administration. Glucorem is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a licensed healthcare provider before making any changes to your health routine or using any dietary supplement. CONTACT: Email: curtisherring@ Phone (US): (888) 308 8896Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Oppenheimer Trims Amazon (AMZN) Price Target to $245 — AI Growth Still a Bright Spot
Inc. (NASDAQ:AMZN) is one of the On August 1, Oppenheimer analyst Jason Helfstein lowered the price target on the stock to $245.00 (from $250.00) while maintaining an 'Outperform' rating. The rating affirmation comes amid frustrated investors over a lack of positive second half 2025 AWS commentary. This is because capacity issues are anticipated to persist until at least year-end. Nevertheless, CEO Jassy has reiterated that artificial intelligence is the 'the biggest technology transformation for a lifetime.' This is already evident considering AWS AI revenue is continuing to grow triple-digits year-over-year and its usage is still early within AWS. The firm doesn't see any consumer weakness despite tariff impacts remaining. Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio
Fast Company
24 minutes ago
- Fast Company
Your next direct report might not be human. Are you ready to lead it?
BY We've spent decades building frameworks to help people lead teams: courses, certifications, coaching, culture decks. All aimed at shaping better managers of humans. But that's no longer enough. Because for many workers, their first report won't be a person. It'll be an agent. In June BNY Mellon onboarded 1,000 digital workers while JPMorgan Chase is building AI teams at scale. This isn't theoretical. The new direct reports are already clocked in and they don't need coffee, feedback, or PTO. The problem? Most organizations are still running on legacy management models built for human hierarchies and not set up to manage machines. Leading humans versus governing agents When you manage people, you guide behavior. You motivate, delegate, coach, and course correct. It's a loop built on trust and conversation. When you manage an AI, none of that applies. You don't coach a model. You govern it. You define inputs, monitor outputs, escalate issues, and answer for the consequences. And you do that in real time. In AI-led teams, leadership is less about motivation and more about judgment. The ability to assess, adjust, and act across decision chains is what separates performance from liability. It's knowing what good looks like. It's catching the drift, asking the right question before the system generates the wrong answer, and being accountable for outcomes, even when you didn't directly produce them. The HR model is out of sync HR isn't ready for this shift. Most performance frameworks still assume linear paths, human reports, and long-term role tenure. But digital agents break that logic. They don't climb ladders. They execute tasks. They can outperform junior staff one day and be outpaced by a new model the next. You don't manage their growth. You manage the conditions in which they operate. That shift puts pressure on organizational design itself. Hierarchies built for human oversight don't hold when decision loops involve systems acting faster than approvals can be processed. That means rethinking how we define productivity, collaboration, and leadership. It means building new metrics for how human employees interact with agents, not just what they produce on their own. Are they designing good prompts? Are they escalating ethical concerns? Are they reviewing outputs critically or rubber-stamping them? These are the new leadership signals. Most performance reviews aren't built to detect them. Prompting is a leadership act Prompting isn't a technical skill; it's a management one. The way you frame a prompt shapes what an agent does. Vague prompts lead to vague results. Biased prompts produce biased outcomes. And poor prompting isn't just inefficient. It can become a legal or reputational risk. Yet most companies treat prompting like its keyboard wizardry. Something for the engineers or the 'AI power users.' That's a mistake. Everyone managing agents, from interns to executives, needs to learn how to design clear, intentional instructions. Because prompts are decisions in disguise, shaped by where they sit in the organizational context and why they're being made. The ethics chain is breaking In traditional teams, ethics and escalation follow a chain of command. Something goes wrong, someone flags it, and a manager gets involved. But with agents acting independently and often invisibly, the chain breaks. You can't escalate what you don't notice. And too often, companies haven't defined what ethical escalation looks like when the actor is synthetic. Who's accountable when an AI produces a discriminatory recommendation? Or leaks sensitive information? Or makes a decision a human wouldn't? If your answer is 'the tech team,' you're not ready. Governance can't sit in the back office. It needs to be built into team workflows. The best companies are training their people to pause, question and report, not just accept what the system spits out. Chain of thought and chain of reasoning aren't just cognitive tricks. They're how human teams will spot drift, bias, and breakpoints in the AI value chain. And that skillset is only going to grow in importance. The bottom line AI won't replace all managers, but it will redefine what management means. Leading agents demands flexing a different muscle and most organizations haven't trained for it. This isn't about replacing soft skills with hard skills, but rather it's replacing passive management with active stewardship: less people-pleasing and more decision accountability, fewer status meetings and more escalation pathways. Managing machines still means leading people. But the people you lead need new tools, new rules, and a different playbook. The companies that get this right won't be the ones with the flashiest tech. They'll be the ones that know how to change the game by managing what they've built. The early-rate deadline for Fast Company's Most Innovative Companies Awards is Friday, September 5, at 11:59 p.m. PT. Apply today. ABOUT THE AUTHOR David Brudenell (DCB) is the executive director of Decidr, Australia's only publicly listed AI company. With 25+ years of experience working across AI infrastructure, model development, and business transformation, David has held senior leadership positions in public, large private and startup companies from Sydney to San Francisco, including Appen (ASX:APX), Pureprofile (ASX:PPL), Eclipx (ASX:FPR), Flare (purchased by MYOB in 2023) and more. More
